Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCRT followed by TPC versus PF adjuvant chemotherapy in high-risk nasopharyngeal carcinoma
ChiCTR1800019373Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cisplatin, paclitaxel, docetaxel and fluorouracil in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
cisplatinpaclitaxeldocetaxelfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1800019373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019373.